# HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

> **NCT05167071** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 53 (actual)

## Conditions studied

- Solid Tumors
- Neuroendocrine Tumors
- CRC

## Interventions

- **DRUG:** HBM4003
- **DRUG:** Toripalimab
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05167071
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-28
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167071, "HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05167071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*